Stereotactic body radiotherapy for multisite extracranial oligometastases: Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease

Cancer

Volumn 118, Issue 11, 2012, Pages 2962-2970

  Salama, Joseph K ^a   Hasselle, Michael D ^b   Chmura, Steven J ^b   Malik, Renuka ^b   Mehta, Neil ^b   Yenice, Kamil M ^b   Villaflor, Victoria M ^b   Stadler, Walter M ^b   Hoffman, Philip C ^b   Cohen, Ezra E W ^b   Connell, Philip P ^b   Haraf, Daniel J ^b   Vokes, Everett E ^b   Hellman, Samuel ^b   Weichselbaum, Ralph R ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

clinical trial; dose escalation; multiple organ metastases; oligometastases; stereotactic body radiotherapy

Indexed keywords

DEXAMETHASONE; FLUORODEOXYGLUCOSE; GABAPENTIN; ONDANSETRON; PROCHLORPERAZINE MALEATE; STEROID;

ABDOMINAL RADIOGRAPHY; ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ADULT; ARTICLE; BLOOD TRANSFUSION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; COMPRESSION FRACTURE; COMPUTER ASSISTED TOMOGRAPHY; EXTRACRANIAL OLIGOMETASTASIS; FATIGUE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; LASER COAGULATION; LIFE EXPECTANCY; LIVER INJURY; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; METASTASIS; MOLECULARLY TARGETED THERAPY; NERVE BLOCK; NEURITIS; OVERALL SURVIVAL; OXYGEN THERAPY; PATIENT SAFETY; PELVIS RADIOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION PNEUMONIA; RADIOFREQUENCY ABLATION; SCORING SYSTEM; STEREOTACTIC BODY RADIATION THERAPY; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR GROWTH;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM METASTASIS; RADIATION DOSAGE; RADIOSURGERY;

EID: 84861334635     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26611     Document Type: Article

References (38)

1. Hellman S, Weichselbaum RR,. Oligometastases. J Clin Oncol. 1995; 13: 8-10.
2. Macdermed DM, Weichselbaum RR, Salama JK,. A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol. 2008; 98: 202-206.
3. Mehta N, Mauer AM, Hellman S, et al. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004; 25: 1677-1683.
4. Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR,. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol. 2009; 48: 578-583.
5. Aloia TA, Vauthey JN, Loyer EM, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006; 141: 460-466; discussion 66-77.
6. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg. 1997; 113: 37-49.
7. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997; 15: 938-946.
8. Wronski M, Arbit E, Burt M, Galicich JH,. Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991. J Neurosurg. 1995; 83: 605-616.
9. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with 1 to 3 brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004; 363: 1665-1672.
10. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322: 494-500.
11. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303: 1070-1076.
12. Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009; 27: 1579-1584.
13. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009; 27: 1572-1578.
14. Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006; 45: 823-830.
15. Salama JK, Chmura SJ, Mehta N, et al. An initial report of a radiation dose-escalation trial in patients with 1 to 5 sites of metastatic disease. Clin Cancer Res. 2008; 14: 5255-5259.
16. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13: 176-181.
17. Cox JD, Stetz J, Pajak TF,. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31: 1341-1346.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
19. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
20. Chang EL, Shiu AS, Mendel E, et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine. 2007; 7: 151-160.
21. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006; 24: 4833-4839.
22. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE,. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005; 62: 1371-1378.
23. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003; 124: 1946-1955.
24. Milano MT, Philip A, Okunieff P,. Analysis of patients with oligometastases undergoing 2 or more curative-intent stereotactic radiotherapy courses. Int J Radiat Oncol Biol Phys. 2009; 73: 832-837.
25. Kao J, Packer S, Vu HL, et al. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer. 2009; 115: 3571-3580.
26. Timmerman RD, Story M,. Stereotactic body radiation therapy: a treatment in need of basic biological research. Cancer J. 2006; 12: 19-20.
27. Yenice KM, Partouche J, Cunliffe A, Farrey K, Weichselbaum RR, Salama JK,. Analysis of radiation pneumonitis (RP) incidence in a phase I stereotactic body radiotherapy (SBRT) dose escalation study for multiple metastases [abstract]. Int J Radiat Oncol Biol Phys. 2010; 78 (3 suppl): S25. Abstract 53.
28. Borst GR, Ishikawa M, Nijkamp J, et al. Radiation pneumonitis after hypofractionated radiotherapy: evaluation of the LQ (L) model and different dose parameters. Int J Radiat Oncol Biol Phys. 2010; 77: 1596-1603.
29. Guckenberger M, Baier K, Polat B, et al. Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol. 2010; 97: 65-70.
30. Wersall PJ, Blomgren H, Lax I, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 2005; 77: 88-95.
31. Miller G, Biernacki P, Kemeny NE, et al. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg. 2007; 205: 231-238.
32. Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008; 26: 1142-1147.
33. Milano MT, Katz AW, Muhs AG, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer. 2008; 112: 650-658.
34. Wulf J, Baier K, Mueller G, Flentje MP,. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol. 2005; 77: 83-87.
35. Wulf J, Guckenberger M, Haedinger U, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006; 45: 838-847.
36. Friedel G, Pastorino U, Buyse M, et al. Resection of lung metastases: long-term results and prognostic analysis based on 5206 cases-the International Registry of Lung Metastases [in German]. Zentralbl Chir. 1999; 124: 96-103.
37. Friedel G, Pastorino U, Ginsberg RJ, et al. Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardiothorac Surg. 2002; 22: 335-344.
38. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005; 366: 643-648.